PA
HRTX icon

Perceptive Advisors’s Heron Therapeutics HRTX Stock Holding History

Perceptive Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-330,000
Closed -$5.33M – 141
2017
Q3 		$5.33M Buy
+330,000
New +$5.18M 0.2% 67
2015
Q3 		– Sell
-448,000
Closed -$14M – 167
2015
Q2 		$14M Buy
+448,000
New +$8.43M 0.84% 33
2015
Q1 		– Sell
-666,042
Closed -$6.7M – 163
2014
Q4 		$6.7M Sell
666,042
-219,310
-25% -$1.79M 0.56% 44
2014
Q3 		$7.38M Sell
885,352
-749,203
-46% -$6.98M 0.75% 36
2014
Q2 		$20.1M Sell
1,634,555
-127,871
-7% -$1.53M 1.98% 15
2014
Q1 		$24.5M Buy
+1,762,426
New +$23.5M 2.58% 9

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors's HRTX Position: Q4 2017 in Review

Perceptive Advisors sold out of Heron Therapeutics (HRTX) in Q4 2017, closing a stake of 330,000 shares — an estimated $5.33M sold.

Perceptive Advisors first reported a position in HRTX in Q1 2014 and held it in 6 quarters. The position peaked at $24.5M in Q1 2014. 124 funds tracked by Wall St. Rank hold HRTX as of Q4 2017.

  • Perceptive Advisors reported no remaining Heron Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Perceptive Advisors sold 330,000 Heron Therapeutics shares in Q4 2017, an estimated $5.33M.
  • Perceptive Advisors first reported a position in Heron Therapeutics in Q1 2014 and held it in 6 quarters.
  • Perceptive Advisors's Heron Therapeutics position peaked at $24.5M in Q1 2014.
  • 124 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2017.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.